GT Biopharma (GTBP)
NASDAQ:GTBP

GT Biopharma Stock Analysis & Ratings

GT Biopharma Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The GT Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

GTBP

GTBP Stock Stats

Previous Close$2.62
Open$2.65
Bid2.4 x 600
Ask3.6 x 100
Today’s Range$2.62 - $2.93
52-Week Range$2.55 - $19.73
Volume138.93K
Average Volume291.93K
Market Cap$81.96M
Beta0.40
P/E Ratio-0.5
EPS-5.01
Earnings DateNov 10, 2021

Company Description

GT Biopharma

GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Anthony J. Cataldo
Employees
2
Website
www.gtbiopharma.com
ISIN
US36254L2097
Address
9350 Wilshire Boulevard, Beverly Hills, CA, 90212, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

GTBP FAQ

What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $2.55 and its highest was $19.73 in the past 12 months.
    What is GT Biopharma’s market cap?
    GT Biopharma’s market cap is $81.96M.
      What is GT Biopharma’s price target?
      The average price target for GT Biopharma is $25.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $26.00 ,the lowest forecast is $25.00. The average price target represents 851.49% Increase from the current price of $2.68.
        What do analysts say about GT Biopharma?
        GT Biopharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is GT Biopharma’s upcoming earnings report date?
          GT Biopharma’s upcoming earnings report date is Nov 10, 2021 which is 72 days ago.
            How were GT Biopharma’s earnings last quarter?
            Currently, no data Available
            Is GT Biopharma overvalued?
            According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
              Does GT Biopharma pay dividends?
              GT Biopharma does not currently pay dividends.
              What is GT Biopharma’s EPS estimate?
              GT Biopharma’s EPS estimate is -$0.2.
                How many shares outstanding does GT Biopharma have?
                GT Biopharma has 30,580,000 shares outstanding.
                  What happened to GT Biopharma’s price movement after its last earnings report?
                  Currently, no data Available
                  Which hedge fund is a major shareholder of GT Biopharma?
                  Currently, no hedge funds are holding shares in GTBP

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis